Provided by Tiger Fintech (Singapore) Pte. Ltd.

KEYMED BIO-B

38.700
-0.300-0.77%
Volume:3.71M
Turnover:138.19M
Market Cap:10.83B
PE:-18.70
High:39.450
Open:36.950
Low:34.150
Close:39.000
Loading ...

KeyMed Biosciences Inc-License Deal Grants Timberlyne Therapeutics Exclusive Right to Develop, Others Cm313 Globally Excl. Mainland China, Others

THOMSON REUTERS
·
10 Jan

KeyMed Biosciences Inc - Unit and Timberlyne Therapeutics, Inc. Entered Exclusive Out-License Agreement

THOMSON REUTERS
·
10 Jan

KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Chronic Rhinosinusitis With Nasal Polyposis

THOMSON REUTERS
·
23 Dec 2024

KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Chronic Rhinosinusitis With Nasal Polyposis

THOMSON REUTERS
·
23 Dec 2024

Keymed Biosciences' Supplemental NDA for Rhinosinusitis Drug Gets China Nod

MT Newswires Live
·
23 Dec 2024

KeyMed Biosciences Inc - Nmpa China Approved Snda of Stapokibart- for Treatment of Chronic Rhinosinusitis- With Nasal Polyposis

THOMSON REUTERS
·
23 Dec 2024

Institutions along with individual investors who hold considerable shares inKeymed Biosciences Inc. (HKG:2162) come under pressure; lose 7.1% of holdings value

Simply Wall St.
·
14 Dec 2024

Keymed Biosciences Unit Grants Exclusive License for Development, Commercialization of Tumor Drug

MT Newswires Live
·
19 Nov 2024

BRIEF-Keymed Says Unit In License Agreement For Platina Medicines To Make Antibody CM336

Reuters
·
17 Nov 2024

KeyMed Biosciences Says Unit in Exclusive License Agreement for Platina Medicines to Make Bispecific Antibody Cm336

THOMSON REUTERS
·
17 Nov 2024

Health Check: How Prudently Does Keymed Biosciences (HKG:2162) Use Debt?

Simply Wall St.
·
22 Oct 2024